LaGasse J, Jelinek L, Sexson S, Lofton-Day C, Breininger J, Sheppard P, Kindsvogel W, Hagopian W A
Department of Medicine, University of Washington, Seattle 98195, USA.
Mol Med. 1997 Mar;3(3):163-73.
We sought to identify novel islet-cell autoantigens to better understand the pathogenesis, prediction, and immunotherapy of type 1 diabetes.
Macaque and human islet cDNA libraries expressed in mammalian cells were screened with human diabetes sera. A positive clone was sequenced directly and after 5' rapid amplification of cDNA ends (RACE). Northern blotting and in situ hybridization revealed the tissue distribution of the corresponding protein. Antigen, expressed by in vitro translation, and tryptic peptides were analyzed by SDS-PAGE. For the immunoprecipitations, 183 diabetic, 60 prediabetic, and 91 control sera were used. Truncated antigens were used in immunoprecipitations for epitope mapping. Recombinant antigen expressed in transfected fibroblasts was used in competition assays.
Sequencing yielded an 111-kDa, 1,013 amino acid, transmembrane protein (M1851) containing consensus protein tyrosine phosphatase (PTPase) sequence. M1851 was 77% identical in the intracellular domain, but only 31% identical extracellularly, to the islet-cell autoantigen ICA512. mRNA localized to brain, prostate, pancreatic islets, and adrenal medulla. After limited trypsinization, the in vitro translated antigen was 37 kDa. M1851 was recognized by 47% of prediabetes sera, 31% of new diabetes sera, but only 1% of healthy controls. Only 1/73 sera binding M1851 failed to bind ICA512, whereas 42/114 binding ICA512 did not bind M1851. M1851 reactivity was not fully displaced by ICA512 in 24/49 sera. Removing the C-terminal 27, 80, or 160 amino acids of M1851 decreased reactivity by 70%, 90%, and 100%, respectively.
This new islet-cell PTPase is likely to be the precursor to the 37-kDa tryptic fragment antigen. It is structurally related to ICA512 but has distinct diabetes autoantibody epitopes located at the C terminus.
我们试图鉴定新的胰岛细胞自身抗原,以更好地理解1型糖尿病的发病机制、预测方法和免疫治疗。
用人糖尿病血清筛选在哺乳动物细胞中表达的猕猴和人胰岛cDNA文库。对一个阳性克隆直接测序,并在进行5' cDNA末端快速扩增(RACE)后测序。Northern印迹和原位杂交揭示了相应蛋白质的组织分布。通过SDS-PAGE分析体外翻译表达的抗原和胰蛋白酶肽段。免疫沉淀实验使用了183份糖尿病患者血清、60份糖尿病前期患者血清和91份对照血清。使用截短的抗原进行免疫沉淀以绘制表位图谱。在竞争实验中使用转染成纤维细胞中表达的重组抗原。
测序得到一种111 kDa、含1013个氨基酸的跨膜蛋白(M1851),其含有共有蛋白酪氨酸磷酸酶(PTPase)序列。M1851在细胞内结构域与胰岛细胞自身抗原ICA512有77%的同源性,但在细胞外仅为31%。mRNA定位于脑、前列腺、胰岛和肾上腺髓质。经有限胰蛋白酶消化后,体外翻译的抗原为37 kDa。47%的糖尿病前期患者血清、31%的新发糖尿病患者血清可识别M185l,而健康对照血清中仅有1%可识别。在与M1851结合的73份血清中,只有1份不与ICA512结合,而在与ICA512结合的1l4份血清中,有42份不与M1851结合。在49份血清中,24份血清中的M1851反应性不能被ICA512完全取代。去除M1851的C末端27、80或160个氨基酸后,反应性分别降低70%、90%和100%。
这种新的胰岛细胞PTPase可能是37 kDa胰蛋白酶片段抗原的前体。它在结构上与ICA512相关,但在C末端有独特的糖尿病自身抗体表位。